Bausch-lomb Incorporated

Bausch + Lomb Ireland Limited

Wyeth Holdings Corporation

Vicki Barniak

Erning Xia

Susan E Burke

William T Reindel

Catherine Scheuer

Joseph C Salamone

Srini Venkatesh

Fang Zhao

John Michael Duex

Andrea E Siverling

Jennifer Marie Hunt

Ivan M Nuñez

Martin J Coffey

Lynn Coullard

Analuz Mark

Praveen Tyle

Eric Phillips

Roya Nicole Borazjani

Ruth Julian

Robert M Braun

John C McMichael

Karl R VanDerMeid

Dexiang Chen

Srini Venkastesh

Keyla M Cubi

David McCanna

Robert Manchester

Jennifer M Hunt

Ivan M Nunez

Ivan M NUÑEZ

A preservative-free contact lens treating solution includes (a) about 0.005 to about 2 wt. %, based on the total weight of the preservative-free contact lens treating solution, of hyaluronic acid or a salt thereof; (b) about 0.01 to about 1 wt. %, based on the total weight of the preservative-free contact lens treating solution, of erythritol; (c) one or more nonionic surfactants; (d) sodium chloride, potassium chloride or any combination thereof; and (e) one or more buffers.

Preservative-free contact lens treating solution comprising hyaluronic acid and erythritol

A packaging system for the storage of an ophthalmic device is disclosed. The packaging system comprises a sealed container containing one or more unused ophthalmic devices immersed in an aqueous packaging solution comprising (a) one or more osmoprotectants, (b) one or more poloxamer comfort agents and (c) one or more polyol demulcents, wherein the aqueous packaging solution has an osmolality of at least about 150 mOsm/kg, a pH of about 6 to about 9 and is heat sterilized.

Packaging solutions

An ophthalmically compatible solution includes (a) about 0.005 to about 2 wt. %, based on the total weight of the ophthalmically compatible solution, of hyaluronic acid or a salt thereof; (b) about 0.01 to about 1 wt. %, based on the total weight of the ophthalmically compatible solution, of erythritol; (c) sodium chloride, potassium chloride or any combination thereof; and (d) one or more buffers.

Ophthalmic solutions

A packaging system for the storage of an ophthalmic device is disclosed. The packaging system comprises a sealed container containing one or more unused ophthalmic devices immersed in an aqueous packaging solution comprising one or more hydrophilic polymers or copolymers comprising hydrophilic units and endcapped with a hydrophobic end group and a hydrophilic end group, wherein the solution has an osmolality of at least about 200 mOsm/kg, a pH of about 6 to about 9 and is heat sterilized.

Contact lens packaging solutions containing hydrophilic polymers endcapped with a hydrophilic and a hydrophobic group

Ophthalmic compositions that comprise 0.1 ppm to 50 ppm of a cationic antimicrobial component selected from the group consisting of biguanides, polymeric biguanides, quaternium ammonium compounds and any one mixture thereof; 0.005 wt. % to 2 wt. % of an anionic biopolymer; and 0.01 wt. % to 2 wt. % of an amphoteric surfactant of general formula I 

Ophthalmic compositions with an amphoteric surfactant and an anionic biopolymer

A packaging system for the storage of an ionic, hydrogel contact lens employs an aqueous packaging solution including a phosphorylcholine polymer. Preferably, the solution has an osmolality of at least about 200 mOsm/kg, a pH of about 6 to about 8 and is heat sterilized.

Ophthalmic compositions that comprise 0.1 ppm to 10 ppm of a cationic antimicrobial component selected from the group consisting of biguanides, polymeric biguanides, quaternium ammonium compounds and any one mixture thereof; 0.005 wt. % to 0.15 wt. % of hyaluronic acid; and 0.01 wt. % to 1.0 wt. % of an amphoteric surfactant of general formula I 

Ophthalmic compositions with an amphoteric surfactant and hyaluronic acid

An aqueous ophthalmic composition comprising a branched, glycerol monoalkyl compound and a fatty acid monoester. The fatty acid monoester comprises an aliphatic fatty acid portion having six to fourteen carbon atoms and an aliphatic hydroxyl portion. The composition will also have an osmolality in a range from 200 mOsmol/kg to 400 mOsmol/kg. The invention is also directed to a method of inhibiting the formation of foam in an aqueous ophthalmic composition that includes a surfactant as well as to a method of enhancing the biocidal efficacy of an aqueous ophthalmic composition containing a fatty acid monoester.

Ophthalmic compositions comprising a branched, glycerol monoalkyl compound and a fatty acid monoester

This invention is directed to an aqueous composition and methods for clean lipid deposits on contact lenses. In particular, a combination of non-ionic surfactants, branched and/or straight poly(ethylene oxide-propylene oxide) (PEO-PPO) block copolymers having HLB value greater than or equal to 18, with an additional straight poly(ethylene oxide-propylene oxide) (PEO-PPO) block copolymers having HLB value less than or equal to 15, has been found to improve the lipid cleaning properties of an aqueous composition for contact lenses and prevent the overgrowth of harmful bacteria, yeast and molds without adversely affecting the comfort or safety in terms of the level of toxicity to eye tissue.

Composition and method for cleaning lipid deposits on contact lenses

A protein from, designated the 74 kD protein, is isolated and purified. The 74 kD protein has an amino-terminal amino acid sequence which is conserved among various strains of. The protein has a molecular weight of approximately 74.9 kD as measured on a 10% SDS-PAGE gel, while its molecular weight as measured by mass spectrometry is approximately 74 kD. The 74 kD protein is used to prepare a vaccine composition which elicits a protective immune response in a mammalian host, to protect the host against disease caused by

74-kilodalton outer membrane protein from Moraxella catarrhalis

Growing community of inventors

Fairport, NY, United States of America

Vicki Barniak